A historical perspective on the discovery and elucidation of the hepatitis B virus.
The discovery in 1965 of the "Australia antigen," subsequently identified as the hepatitis B virus surface antigen (HBsAg), was such a watershed event in virology that it is often thought to mark the beginning of hepatitis research, but it is more accurately seen as a critical breakthrough in a long effort to understand the pathogenesis of infectious hepatitis. A century earlier, Virchow provided an authoritative explanation of "catarrhal jaundice," which did not consider an infectious etiology, but the transmission of jaundice by human serum was clearly identified in two outbreaks in 1885, and the distinction between "infectious" and "serum" hepatitis was recognized by the early 1920s. The inability to culture a virus or reproduce either syndrome in laboratory animals led to numerous studies in human volunteers; by the end of World War II, it was known that the diseases were caused by different filterable agents, and the terms "hepatitis A" and "B" were introduced in 1947 (though some long-incubation cases then designated B must in retrospect have been hepatitis C). The development of a number of liver function tests during the 1950s led to the recognition of anicteric infections and the existence of chronic carriers, but little more could be done until an infectious agent had been identified. Once Blumberg and colleagues had found a specific viral marker, the vast amount of accumulated epidemiologic and clinical data, together with huge numbers of stored serum samples, enabled rapid progress in understanding hepatitis B, and revealed the existence of a vast population of chronically infected people in Asia, Oceania and Africa. In this article, we place the identification of the Australia antigen within the historical context of research on viral hepatitis. Following a chronological review from 1865 to 1965, we summarize how the discovery led to improved safety of blood transfusion, the development of a highly effective vaccine and the eventual identification of the hepatitis C, D and E viruses. This article forms part of a symposium in Antiviral Research on "An unfinished story: from the discovery of the Australia antigen to the development of new curative therapies for chronic hepatitis B."
Baruch S. Blumberg Institute, 3805 Old Easton Road, Doylestown, PA 18902, USA. Electronic address: tim.block@bblumberg.org.
Timothy M
TM
Block
Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD 20892, USA.
Harvey J
HJ
Alter
Fox Chase Cancer Center, Philadelphia, PA 19046, USA.
W Thomas
WT
London
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mike
M
Bray
D000349:Africa / Q000453:epidemiology; D000818:Animals; D001208:Asia / Q000453:epidemiology; D006506:Hepatitis A / Q000266:history / Q000821:virology; D006509:Hepatitis B / Q000453:epidemiology / Q000266:history* / Q000635:transmission / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000266:history* / Q000302:isolation & purification; D006515:Hepatitis B virus / Q000145:classification / Q000302:isolation & purification* / Q000472:pathogenicity; D019694:Hepatitis B, Chronic / Q000453:epidemiology / Q000266:history / Q000628:therapy / Q000821:virology; D006526:Hepatitis C / Q000266:history / Q000821:virology; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D051379:Mice
D006514:Hepatitis B Surface Antigens